111.14
-7.85 (-6.60%)
| Previous Close | 118.99 |
| Open | 119.89 |
| Volume | 662,660 |
| Avg. Volume (3M) | 615,730 |
| Market Cap | 3,998,109,440 |
| Price / Earnings (TTM) | 76.12 |
| Price / Sales | 5.28 |
| Price / Book | 6.27 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 7.42% |
| Operating Margin (TTM) | 12.84% |
| Diluted EPS (TTM) | 1.95 |
| Quarterly Revenue Growth (YOY) | 1.10% |
| Quarterly Earnings Growth (YOY) | 44.50% |
| Total Debt/Equity (MRQ) | 57.49% |
| Current Ratio (MRQ) | 2.56 |
| Operating Cash Flow (TTM) | 157.37 M |
| Levered Free Cash Flow (TTM) | 152.43 M |
| Return on Assets (TTM) | 5.75% |
| Return on Equity (TTM) | 9.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Scientific & Technical Instruments (US) | Bullish | Mixed |
| Scientific & Technical Instruments (Global) | Bullish | Mixed | |
| Stock | Novanta Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.80 |
|
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe. |
|
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Investment Style | Small Core |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 105.06% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BUCKLEY ROBERT | - | 140.75 | -1,423 | -200,287 |
| GLASTRA MATTHIJS | - | 140.75 | -7,500 | -1,055,625 |
| Aggregate Net Quantity | -8,923 | |||
| Aggregate Net Value ($) | -1,255,912 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 140.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GLASTRA MATTHIJS | Officer | 21 Jan 2026 | Automatic sell (-) | 7,500 | 140.75 | 1,055,625 |
| BUCKLEY ROBERT | Officer | 21 Jan 2026 | Automatic sell (-) | 1,423 | 140.75 | 200,287 |
| BUCKLEY ROBERT | Officer | 21 Jan 2026 | Option execute | 1,423 | - | - |
| Date | Type | Details |
|---|---|---|
| 22 Jan 2026 | Announcement | Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026 |
| 18 Dec 2025 | Announcement | Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026 |
| 15 Dec 2025 | Announcement | Novanta to Present at the J.P. Morgan 44th Annual Healthcare Conference on Wednesday, January 14, 2026 |
| 07 Nov 2025 | Announcement | Novanta Inc. Announces Pricing of $550,000,000 Tangible Equity Units Offering |
| 05 Nov 2025 | Announcement | Novanta Inc. Announces Offering of Tangible Equity Units |
| 03 Nov 2025 | Announcement | Novanta Announces Financial Results for the Third Quarter 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |